Advertisement
Singapore markets open in 11 minutes

  • Straits Times Index

    3,343.35
    +11.65 (+0.35%)
     

  • S&P 500

    5,482.87
    +4.97 (+0.09%)
     

  • Dow

    39,164.06
    +36.26 (+0.09%)
     

  • Nasdaq

    17,858.68
    +53.53 (+0.30%)
     

  • Bitcoin USD

    61,517.52
    +701.54 (+1.15%)
     

  • CMC Crypto 200

    1,281.31
    +15.17 (+1.20%)
     

  • FTSE 100

    8,179.68
    -45.65 (-0.55%)
     

  • Gold

    2,334.90
    -1.70 (-0.07%)
     

  • Crude Oil

    81.95
    +0.21 (+0.26%)
     

  • 10-Yr Bond

    4.2880
    -0.0280 (-0.65%)
     

  • Nikkei

    39,635.77
    +294.23 (+0.75%)
     

  • Hang Seng

    17,716.47
    -373.46 (-2.06%)
     

  • FTSE Bursa Malaysia

    1,584.94
    -6.01 (-0.38%)
     

  • Jakarta Composite Index

    6,967.95
    -6,905.64 (-49.78%)
     

  • PSE Index

    6,390.58
    +77.47 (+1.23%)
     

Compared to Estimates, Clarivate (CLVT) Q1 Earnings: A Look at Key Metrics

Zacks Equity Research
·2-min read

Clarivate PLC (CLVT) reported $621.2 million in revenue for the quarter ended March 2024, representing a year-over-year decline of 1.3%. EPS of $0.14 for the same period compares to $0.18 a year ago.

The reported revenue represents a surprise of +1.08% over the Zacks Consensus Estimate of $614.57 million. With the consensus EPS estimate being $0.14, the company has not delivered EPS surprise.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Clarivate performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenue- Intellectual Property: $200.90 million versus the four-analyst average estimate of $197.04 million. The reported number represents a year-over-year change of -3.9%.

  • Revenue- Life Sciences and Healthcare: $102.60 million versus the four-analyst average estimate of $100.92 million. The reported number represents a year-over-year change of -2.6%.

  • Revenue- Academia and Government: $317.70 million versus $315.73 million estimated by four analysts on average.

  • Revenue- Transactional Revenue: $115.60 million compared to the $101.08 million average estimate based on two analysts.

  • Revenue- Re-occurring revenues: $102.50 million compared to the $106.88 million average estimate based on two analysts.

  • Revenue- Subscription Revenue: $403.10 million versus $407.80 million estimated by two analysts on average.

View all Key Company Metrics for Clarivate here>>>

Shares of Clarivate have returned -9.2% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Clarivate PLC (CLVT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research